General Information
Version
8.3
Revision date
2024-01-26
Product name
Citalopram hydrobromide
CAS No.
59729-32-7
REACH No
is
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H336, H361d, H412
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Warning Warning
Hazard statements
H302 Harmful if swallowed. H336 May cause drowsiness or dizziness. H361d Suspected of damaging the unborn child. H412 Harmful to aquatic life with long lasting effects. Reduced Labeling (<= 125 ml) H412 Harmful to aquatic life with long lasting effects. H361d Suspected of damaging the unborn child.
Precautionary statements
P201 Obtain special instructions before use. P273 Avoid release to the environment. P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P201 Obtain special instructions before use. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
